Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Young Muslims in Germany feel left out of Mideast debate, experts say - 2November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
- 3Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- 4Wait, it's 'Harry Potter and the Philosopher's Stone'? Why the new HBO series name is significant to Americans
- 5PHOTO ESSAY: Scientists trying to unravel one of the body's biggest mysteries
- Los Angeles County sees significant uptick in norovirus cases, officials say
- Charli xcx teases new film ‘The Moment’: What to know about the A24 movie
- When will the Epstein files be released — and will they reveal anything new?
- Charlotte faith leaders hold interfaith forum on Black and Palestinian solidarity
- Israel reports second missile fire from Yemen since start of Iran war
- Step by step instructions to Pick A Pre-owned vehicle Stage
- Pick Your Favored kind of sandwich
- Black Friday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- 10 Moving Design Frill for Summer 2023
